57% Reduction in Total Cholesterol from Nyrada’s NYX-PCSK9i In Vivo Study Jan 25, 2021 ASX News Nyrada Inc (ASX:NYR) Send Share Share
Positive pre-IND meeting with US FDA and ethics approval to commence Phase 2a Psi-GAD clinical trial: psilocybin-assisted psychotherapy for Generalised Anxiety Disorder Oct 28, 2021 | ASX News, Incannex Healthcare (ASX:IHL)
Incannex submits HREC proposal and FDA pre-IND meeting request for Psi-GAD psilocybin therapy for Generalised Anxiety Disorder Aug 13, 2021 | ASX News, Incannex Healthcare (ASX:IHL)
Cholesterol-Lowering Program Delivers Two New Potent Drug Candidates May 5, 2021 | ASX News, Nyrada Inc (ASX:NYR)